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Abstract 
 
Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) activity 
has been found to be dysregulated in cancer cells and therefore is a crucial 
target for research. Only a few LPA receptors have been identified to date, 
namely LPA 1, LPA 2, LPA 3, LPA 4 and peroxisome proliferator-activated 
receptors (PPAR). In order to identify receptors, we are designing and 
synthesizing bifunctional LPA and LPC activity probes to characterize their 
protein targets using activity based protein profiling (ABPP) among other 
proteomic technologies. By synthesizing bifunctional signaling probes that can 
mimic the naturally occurring LPA and LPC molecules and selectively capture 
receptors by virtue of their binding properties, we can identify and study the 
different proteins that are aberrantly expressed in various pathophysiological 
states such as cancer. 
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CHAPTER I  
INTRODUCTION  
 
Lipids are naturally occurring molecules that play important biological 
functions. They are integral structural components of cell membranes and are 
important signaling molecules. Eukaryotic cells are composed of a 2-molecule 
thick lipid bilayer, which primarily consists of phospholipids containing a 
hydrophilic head group and two hydrophobic tails each.1 The polar head groups 
are directed towards the inside (cytoplasm) and to the outside (extracellular 
matrix). For a long time, lipids were thought to have minimal biological roles that 
were limited to composition of cell membranes and as intermediates in lipid 
biosynthesis2. However, later studies revealed how lipids play key roles in cell 
signaling that governs specific cellular responses.3 The most abundant 
glycerophospholipids in cells, phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE), had been regarded as passive structural 
components of cell membranes for a long period of time.4 However, studies by 
Hokin and Hokin in 1950 described how phosphatidylinositol turnover is induced 
by acetylcholine.2 This, alongside with studies by Takai and Kishimoto, which 
revealed that their enzymatic activity as cyclic nucleotide-independent kinase is 
activated by the active phospholipids in membranes, implies that membrane-
bound lipids play a crucial role in the transmembrane control of important 
biological processes and organelle biogenesis, thus underlying their active rather 
than passive role in biochemistry of eukaryotic cells.2-3 Studies have shown that 
lipid signaling is a vital component of cell signaling and often involves the binding 
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of  lipids to protein targets, such as receptors, kinases or phosphatases, which in 
turn mediates the effects of these intermediate lipids in important biological 
pathways.  
Background and Significance of Lipid Signaling and LPA activity 
Monoacyl-sn-glycero-3-phosphate, commonly known as lysophosphatidic 
acid (LPA, figure 1) has aroused substantial research interest in the recent past, 
as its growth-factor-like activity has been found to be upregulated in cancer cells. 
The causal role of LPA in cancer is substantiated by studies showing that 
metastasis is characterized by increased activity of the enzyme autotaxin, which 
produces LPA. Today LPA is known to contribute towards several physiological 
and pathophysiological processes in vivo. The discovery of the mitogenic nature 
of LPA and its signaling via specific G-protein coupled receptors (GPCRs) in the 
1990s stimulated its emergence as a crucial target for research.5 LPA is today 
not only known to be active in several and diverse G-protein-mediated signaling 
pathways6, but also activates Ras and Rho/Rac family GTPases to control cell 
multiplication, migration and morphogenesis, respectively, and therefore also 
plays a role in wound healing and atherosclerosis among other processes. LPA 
has been found to be produced in diverse cell types including Schwann cells, 
leukocytes, T-lymphoma cells, skin, myofibroblasts, cortical cells, neuronal and 
non-neuronal cells.7 In addition, LPA levels are increased in a number of 
pathophysiological states including immunodeficiency diseases, ovarian and 
other cancer cells and atherosclerosis. This implicates LPA as an important 
mediator in the onset of cancer.8  
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Figure 1. LPA metabolic pathways 
Therefore, LPA synthesis, signaling, receptors, bioactivity and degradation are 
crucial targets for research and therapy of cancer and other diseases. 
Lysophosphocholine (LPC, figure 1), is a critical glycerophospholipid 
because it acts as a substrate for the enzyme autotaxin (ATX), which performs 
phosphate hydrolysis to produce lysophosphatidic acid (LPA). Consequently, it is 
an important therapeutic target in medicinal chemistry. However, few inhibitors of 
autotaxin are known so far to have drug like properties. The first ATX-directed 
fluorescent activity probe has been synthesized and characterized by Cavalli et 
al.in 2010, that detects and quantifies ATX activity under normal and pathological 
conditions.9 This probe contains a trapping moiety that becomes reactive after 
phosphate ester hydrolysis,and then, specifically and covalently binds to the 
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active site of ATX. Their study highlights the potential of such ATX-specific ABPs 
to be used as diagnostic reagents.9 
Biosynthesis of LPA 
LPA is synthesized in living systems both intracellularly and extracellularly. 
Inside the cell, LPA is produced and used as an intermediate for the synthesis of 
phospholipids. There is no evidence that this intracellular LPA is then released 
into the extracellular environment. LPA is present in saliva, seminal fluid, 
incubated plasma, follicular fluids and serum, but not in plasma, as is produced 
only during serum formation. Ovarian cancer cells and platelets produce LPA 
upon stimulation.7 
LPA is produced by two enzymatic mechanisms: a) hydrolysis of the fatty 
acyl chain of phosphatidic acid (PA) at the sn-2 position by phospholipase  A2 
(PLA2), or at the sn-1 position by phospholipase A1 (PLA1) (mainly operative 
intracellularly); and b) Hydrolysis of membrane LPC (Lysophosphatidylcholine) 
by autotaxin, which removes the hydrophilic choline headgroup (in extracellular 
body fluids like serum) (Figure 1).8 Lysophospholipase D (lysoPLD), which 
catalyses the production of LPA from LPC, is identical to autotoxin(ATX).10 Both 
LPA and LPC contain a single fatty acyl chain. When PLA1 cleaves the sn-1 fatty 
acid, it produces sn-2 and polyunsaturated LPA isoforms, which are active on 
LPA receptor 3.11 Type-II secretory phospholipase A2 (sPLA2) cleaves the sn-2 
acyl chain, but is incapable of hydrolyzing lipids in intact cell membranes, 
resulting in low LPA levels in the plasma. However, sPLA2 can selectively 
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hydrolyze lipids in damaged micro vesicles and cells that are produced in 
malignant fluids leading to abnormally high LPA levels in cancer cells.8  
The protein ATX was first isolated in the early 1990s as an 
„autocrine/tumor motility factor‟ produced by human melanoma cells and later 
characterized as a member of the ecto-nucleotide phosphodiesterase 
/pyrophosphatase (NPPs) family of enzymes that hydrolyze phosphodiester and 
pyrophosphate bonds in ATP and ADP.12 ATX has been found to be upregulated 
in several cancers (including lung, renal-cell, mammary, hepato-cellular 
carcinoma) and is expressed in the highest levels in brain, ovary, kidney, lung, 
intestine, and testis.13 ATX is a type II transmembrane protein with a short amino-
terminal region, a single transmembrane domain, two cysteine rich 
somatomedin-B-like domains and a large catalytic domain. Studies have shown 
that the motility-stimulating activity of ATX is attributed to production of LPA from 
LPC, and the detection of elevated ATX expression in malignant tumor cells 
provides enough evidence for the role of LPA in the onset of cancer.14 Therefore, 
ATX converts extracellular LPC into receptor-active LPA, which stimulates 
malignant cell proliferation and differentiation of adipose tissue. The mechanism 
that has been proposed for cancer cell motility is through the activation of G-
protein-coupled receptor LPA1. ATX is also upregulated in genetically obese 
mice. In addition, LPA exists in extracellular fluid of adipocytes and is released by 
adipocytes in vitro. These studies suggest ATX mediating LPA paracrine control 
of adipose tissue.15 
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LPA has been termed as a double-edged sword. Studies have elucidated 
physiological roles of LPA in the reproductive system, embryonic development, 
wound healing, tissue repair, blood clotting and to maintain homeostasis of the 
body against stress. However, it simultaneously plays a key role in the initiation 
and propagation of various human malignancies and pathological processes. 
Studies suggest both a protective (under ischemia) and destructive (as causes 
atherosclerosis) role of LPA in different aspects of cardiovascular disorders. LPA 
has been identified as a growth factor for cancer (ovarian, prostate, breast, lung, 
gastric, pancreatic, colorectal cancer) cells by inducing cell proliferation, growth, 
survival, migration, invasion and angiogenesis. Also, recent studies indicate a 
significant contribution of LPA signaling to neuropsychiatric disorders and 
neuropathic pain. In addition, LPA‟s involvement in not only the male and female 
reproductive systems, but also in embryonic development, can help develop new 
assisted reproductive technologies and birth control. This functional switch of 
LPA from physiological to pathophysiological mechanisms underscores its 
signaling and identification of its receptors as a crucial therapeutic target for 
prevention and treatment of various diseases like cancer. As illustrated by these 
examples, LPA shows both a positive and a negative role in pathological 
processes and has a contribution in normal physiological processes, and 
therefore is the primary focus of my research. 
LPA Receptors 
So far, five distinct LPA receptors (LPA1-LPA5) have been identified that 
mediate LPA activity. Due to their sequence homology, LPA 1, LPA 2 and LPA 3 
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receptors belong to the endothelial differentiation gene (EDG) sub-family of the 
GPCR superfamily (therefore also called EDG 2, EDG 4 and EDG 7, 
respectively) which traverses the membrane seven times.7 LPA 4 was identified 
recently, which is more closely related to the Purinergic family, and shares no 
significant similarity with the EDG family.7 LPA 1, the first discovered receptor, is 
most widely expressed and best characterized, whereas LPA2 and LPA 3 have a 
more restricted distribution, and expression of LPA 4 is very low in most human 
tissues, but significant in the ovary.8 Although LPA5  is structurally different from 
LPA1-3, but it shares 35% homology with LPA4.
16 A probable sixth LPA receptor, 
LPA6, has been reported recently. LPA6 is closely related to LPA4, and is 
essential for human hair growth.17 
LPA 1 is most widely expressed with high mRNA levels in the colon, small 
intestine, placenta, brain, heart, and significantly high levels in cerebral cortical 
ventricular zone during neurogenesis, adult oligodendrocytes and Schwann cells, 
in addition to moderate expression in pancreas, ovary and prostate.8 Expression 
of LPA 2 and LPA 3 receptors is elevated in cancer cells, especially in ovarian 
cancer cells, thereby suggesting a potential role in ovarian cancer progression. 
LPA1, LPA2 and LPA3 receptors of the EDG family exhibit 50% sequence 
homology in amino acid sequences in all areas except that of the carboxy (C)-
terminal tail region of these receptors is much less homologous with only 27% 
between LPA1 and LPA2, and 17% between LPA2 and LPA3 receptors. This 
difference in sequences of amino acids only in the C-terminal tail domain could 
be a possible reason for the specificity of the receptors in mediating LPA 
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signaling.7 Experiments were conducted in a yeast two-hybrid screening by Xu et 
al. to understand the mechanisms and specificity by which these LPA receptors 
mediate LPA activity, and found that TRIP 6 (a focal adhesion molecule) 
specifically binds to carboxyl-terminal tail of the LPA 2 receptor through its LIM 
domains and not other LPA 1 or LPA 3 receptors.18 This specific interaction 
between TRIP 6 and LPA2 alone might help to study the specific roles of LPA2 in 
the pathophysiology of ovarian cancer cells. 
G-protein-coupled receptors (GPCRs) and G-protein signaling 
The reason why LPA signals are involved in diverse biological and 
physiological processes, such as tissue remodeling, neurogenesis, immune, 
reproductive functions, wound healing, cancer, atherosclerosis, is because LPA 
receptors can couple to at least 3 different heterotrimeric proteins - Gq, Gi and 
G12/13, which further feed into multiple effector pathways.
7 The major downstream 
effectors are shown in figure 2. LPA activates Gq, which stimulates 
Phospholipase C (PLC), stimulating the hydrolysis of phosphatidylinositol-(4,5)-
bisphosphate (PIP2) to diacylglycerol (DAG) and Inositol-(1,4,5)-trisphosphate 
(IP5). 
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Figure 2. Major LPA signaling pathways involving G-coupled receptors 
 
 LPA also activates Gi, which feeds into 3 different signaling routes a) 
inhibition of adenyl cyclase b) G-mediated stimulation of mitogenic RAS-MAP 
kinase (mitogen-activated protein kinase) cascade, thus triggering downstream 
events, and c) activation of phosphatidylinositol-3-kinase (PI3K), which leads to 
the activation of the guanosine diphosphate/guanosine triphosphate (GDP/GTP) 
exchange factor TIAM 1 and the downstream RAC GTPase, in addition to 
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activation of AKT‟s ‟survival‟ pathway to promote cell movement and prevent cell 
death or apoptosis. Lastly, LPA activates G12/13, which stimulates GTPase RHO 
A, plays a role in cytoskeletal contraction and cell rounding.7 Therefore, LPA, in 
addition to activating second messengers such as cAMP, calcium and 
diacylglycerol, also stimulates RAS and RHO family GTPases, which are master 
switches that control cell proliferation, migration and morphogenesis8 (Figure 2). 
LPA induced activation of Gi in turn stimulates the RAS-mediated 
downstream MAP kinase cascade and plays a role in DNA synthesis, cell 
proliferation and cell survival. The mechanism of Gi coupling to Ras is complex 
and not yet clear. In order to maintain proper cell functionality, the accumulated 
LPA must be counterbalanced by inactivation processes. It has long been known 
that extracellular LPA in mammalian cells is degraded by removal of a phosphate 
group to produce biologically inactive monoacylglycerol.  
Activity Based Protein Profiling (ABPP) 
Advances in genome sequencing techniques have provided useful 
insights into the crucial aspects of the proteome encoded by genomes. 
Techniques such as chromosomal translocation, transcriptional profiling, and 
RNA interference based gene silencing have enlightened us about the 
physiological and pathological processes of genome sequences, which are 
controlled by proteins and RNA molecules.19 Nevertheless, they do not furnish 
information about the post-translational events that regulate protein function and 
activity. To overcome this problem, several proteomic strategies have been 
developed including LC-MS, gel electrophoresis, multidimensional protein 
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identification technology (MudPIT) and isotope coded affinity tags (ICAT), yeast 
two–hybrid systems, and protein microarrays that enrich the knowledge of the 
functions of proteins in vitro.20 However, they fail to assess protein‟s functional 
state and activity inside cells and tissues.21 Therefore, as a complement to 
conventional genomic techniques, ABPP has been developed as a functional 
proteomic technology to identify and understand the functional state of novel 
proteins, and characterize proteins on the basis of activity rather than 
abundance.20 
The chemical proteomic approach of ABPP uses active-site directed 
probes to collectively analyze proteins based on activities. ABPP probes use a 
range of mechanism-based inhibitors, protein-reactive natural products and 
general electrophiles to target and react with specific classes of enzymes sharing 
a similar catalytic activity. 
The basic unit of ABPP is a probe that typically consists of two elements: 
(1) a reactive group by which the probe selectively and covalently cross-links to 
residues in the active site of an active enzyme. (2) a secondary tag that may be 
either a reporter group such as fluorophore, biotin, or a latent analytical handle 
such as alkyne or azide that can undergo derivatization via click chemistry to 
visualize and purify target proteins. These groups are incorporated into an active 
molecule such that it mimics the natural compound. Therefore, ABPP involves 
the synthesis of small-sized probes that can covalently label active site residues 
of target proteins, as shown in figure 3. Subsequently, the labeled proteins are 
visualized and purified using the secondary reporter tag, commonly alkyne or 
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azide tags attached on the probe are reacted with complementary “clickable” 
fluorophores or biotin bearing azide or alkyne, respectively, forming a 1,4-
disubstituted triazole product which covalently introduces these tags on to the 
probe-labeled protein facilitating analysis. This is performed by gel fluorescence 
scanning for fluorescent probes or by purification on a streptavidin column for 
biotinylated probes, which is followed by mass spectrometry analysis for 
identification of the probe-labeled enzymes.19 
Today, ABPP is being used in multiple biological experiments including 
the discovery of protein targets using comparative ABPP, as well as inhibitor 
identification and enzyme active site characterization. ABPP has many 
advantages over other conventional methods for target discovery as it can 
account for the post-translational mechanisms that regulate enzyme activity and 
labels even low-abundance proteins. The inhibitor discovery involves competitive 
ABPP to identify inhibitors which are able to block probe labeling of enzymes. 
The advantage of this method is that it does not require recombinant expression 
and purification as the enzymes are tested within the proteome. Also, ABPP is a 
powerful tool to assign an uncharacterized enzymes to a specific mechanistic 
class and recognize new enzyme active sites.19 
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Figure 3. Schematic representation of Activity Based Protein Profiling 
(ABPP) using probes bearing photoaffinity tags 
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Figure 4. Examples of photo-reactive groups 
Photo affinity labeling (PAL) involves a specific covalent binding between 
a light-sensitive chemical tag and  the active site of a receptor protein molecule 
upon irradiation, in a specifically and reversibly bound state.22 This enables 
specific cross-linking of the ligand to the specific protein targets to which it 
preferentially binds. This identification of drug-receptor pairs helps to design drug 
molecules that show selective recognition of specific targets associated with a 
specific pathology. A photo reactive group should be stable to ambient light, and 
its excited state should have a lifetime long enough to abstract a hydrogen on 
carbon atom to form a cross link with the target protein. Also, its UV excitation 
wavelength should be higher than the absorption range of most proteins. 
Commonly used groups are shown in Figure 4. Phenyl azides are usually the first 
choice to use as they are easy to prepare. Diazirines are very stable before UV 
irradiation and need wavelengths higher than that for proteins, but require mult-
step synthesis to form the strained 3-membered heterocyclic rings. The 
benzophenone probe requires prolonged irradiation resulting in cell death, but 
the excited carbonyl diradical is less reactive towards water than a nitrene or 
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carbene.22a Therefore, benzophenone is being used as a photoprobe for the 
synthesis of my analogues since it is easily activated with long wavelength UV 
light, and is stable during the chemical reactions used for the probe synthesis.  It 
also has been found to covalently modify a single protein target.23  
Photoactivable lipid analogues have been used earlier to determine 
structure of membrane-bound proteins.24 Studies published by Li et al., report the 
synthesis of a benzophenone photoactivable analogue of acyl-LPA, with an 
oleoyl (ester) chain.22 Previous structure- activity studies have found that the 
oleoyl chain most closely represents the fatty acyl chain of naturally occurring 
LPAs.25 This probe was found to covalently modify protein targets in rat 
plasma.22 
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Chapter II: Research Design 
 
The biological properties of LPA and LPC have been studied widely but 
their roles and activity in many pathophysiological conditions are not yet 
completely understood. Therefore, we are designing photoreactive analogs of 
LPA and LPC in order to track and elucidate their activities in the biological 
systems. This research project targets the development of bifunctional LPA and 
LPC analog probes, as shown in figure 5. These probe designs consist of LPA 
and LPC analogs. A Y-shaped lysine linker bearing both a photoaffinity 
benzophenone group as well as a clickable reactive azide or alkyne reporter tag, 
is used as a secondary handle to append a fluorophore or biotin tag. These 
probes will allow for selective labeling of target proteins, followed by visualization 
and purification on a streptavidin column for the selective enrichment and 
identification of crosslinked proteins. 
 
 
 
 
Figure 5. Target LPA & LPC activity probes 
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As shown in figure 6, the head group synthesis started with the protection 
of the free alcohol of (S)-glycerolacetonide 2 with a p-methoxybenzyl protecting 
group to 3, followed by acetal deprotection to produce diol 4. Next, the primary 
alcohol of 4 was selectively protected by monomethoxytrityl chloride (MMTrCl) to 
5, followed by secondary alcohol protection using tert-butyldiphenylsilyl chloride 
to yield 6. Next, the MMTr group was deprotected using camphorsulfonic acid 
producing 7 with a free alcohol at the sn-1 position.  
The synthesis of the lipid tail containing the benzophenone cross-linking 
group and azide tag (Figure 7) began with the coupling of 4-benzoylbenzoic acid 
to a Y-shaped protected lysine linker 8 to produce 9. The Boc protecting group 
was removed using trifluoroacetic acid to produce the free amine of 10, and in 
order to keep the synthetic strategy modular (figure 8), 10 was converted  into 
both an azide 12a and alkyne 12b, the latter by reacting with alkyne acid 11. 
After the azide/alkyne methyl esters 12a and 12b were purified, they were 
hydrolyzed to yield acids 13a and 13b, respectively. 
                              Coupling of Head group and Lipid tail 
Once synthesized, we attempted to couple head group 7 and lipid tail 
13a/b  to produce 21, as shown in Figure 9. The coupling of alcohol 7 with the 
azide and alkyne acids 13a and 13b was attempted several times using different 
coupling reagents, including  N,N–dicyclohexylcarbodiimide (DCC), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and thionyl chloride ( SOCl2), but  the 
reaction never gave very good yields, and the product was difficult to 
characterize. It may be attributed to the steric hindrance at the alcohol reaction 
  18 
center, caused by the two bulky protecting groups. Therefore, to get around this 
problem, another synthetic strategy was followed in which we attempted to 
couple the acid directly with the diol, and the mixture of 1 and 2 substituted 
products would be separated to obtain the latter, and this would be followed by 
the protection of the secondary alcohol. Therefore, a set of trial reactions were 
run in order to find out the best reaction conditions for the coupling of the diol 
with  lauric acid as it is similar to the lipid tail, as shown in figure 10. The  best 
results were obtained with EDCI and DCC coupling reagents as they yielded the 
highest yields of the desirable regioisomeric ester, and the two regioisomers 
were conveniently separated. Next, the diol and the lysine acid were coupled 
under these reaction conditions, as shown in figure 11, but again the yields were 
not very good.  
  Once they have been coupled, the p-methoxybenzyl group of 21a,b 
would then be deprotected with DDQ to yield the free alcohol 14a,b (Figure 12). 
This would be followed by the installation of protected phosphoramidites 19 or 
20, as shown in figure 10 and 11. Finally the dibenzyl and ethylcyano groups of 
17a/b and 15 a/b respectively, will be deprotected producing the free phosphate, 
followed by the deprotection of TBDPS group to produce the target LPA activity 
probes 18a/b and LPC activity probes 16a/b, that can be utilized to identify and 
characterize new protein targets. 
Once the bifunctional probes have been synthesized, they will first be 
tested for their effective activity as LPA and LPC mimics by the means of TLC 
(exploiting the differential adsorption of LPA and LPC on a TLC plate), MS 
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studies and fluorescence resonance energy transfer (FRET) through our ongoing 
collaborations with Dr. Daniel L. Baker and Dr. Abby L. Parrill at the University of 
Memphis. After it is validated as an effective mimic, it will be then be subjected to 
ABPP and other analytical studies, again in collaboration, where the incubation of 
the proteome with our synthesized probes will be followed by UV irradiation and 
fluorophore or biotin–labeling of the probe–bound proteins. Next, this mixture of 
proteins will be separated using electrophoresis (1D or 2D polyacrylamide gel 
electrophoresis PAGE), and the labeled proteins will be detected by fluorescence 
scanning of the gels.19 Proteins labeled with biotinylated probes will be separated 
by affinity chromatography using a streptavidin column. Though ”gel-free” 
methods have emerged, gel-based methods are still widely used because of their 
robustness and efficiency. Liquid chromatography-mass spectrometry (LC–MS) 
methods provide better resolution than the gel–based methods, and is classified 
into two types. The first type involves the analysis of protein targets of probes, 
and the second one specifically analyses probe-labeled peptides derived from 
these targets. The first method is a combination of ABPP and MudPIT 
(multidimensional protein identification technology), in which biotinylated probe-
labeled enzymes are enriched on streptavidin column, followed by enzymatic 
digestion (with trypsin)  of  the protein into peptide fragments that are then 
analyzed by LC-MS using triple-quadruple and ion trap mass spectrometers. The 
disadvantage of this method is that it does not offer a straightforward way to 
identify probe labeled peptides of enzyme targets.19 Therefore, active–site 
peptide profiling (ASPP) is used, which reverses the order of enzymatic digestion 
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and incubation, followed by the use of SEQUEST algorithm to identify protein 
receptors and sites of probe labeling. Speers and Cravatt developed tandem 
orthogonal proteolysis–ABPP (TOP–ABPP), which combined the advantages of 
ABPP–MudPIT and ASPP to complement each other. In TOP, the probe-labeled 
proteins are clicked with a biotin tag bearing a tobacco etch virus protease (TEV) 
cleavage site, and then enriched. Following the on-bead tryptic digestion of the 
tagged proteins, the probe-labeled peptides are eluted from the beads by 
incubation with TEV. Then sequential MudPIT experiments are conducted to 
analyze the trypsin and TEV digests, for characterizing the probe-labeled 
proteins and sites of probe labeling.26 Though LC-MS offers high resolution, but 
requires larger sample volume each time and is slower, and thus not a desirable 
method to analyze hundreds of samples.19 
These analytical methods will help us to identify the inhibitors of LPA production 
and action. 
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Figure 6. Synthesis of the head group 
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Figure 7. Synthesis of the lipid tail 
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Figure 8. Modular synthesis of the alkyne acid 
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Figure 9. Synthetic strategy for introducing the bifunctional tag
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Figure 10. Alternative methods attempted for direct coupling of lipid tails 
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Figure 11. Attempt to couple bifunctional tags directly onto diol 4  
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Figure 12. Modular synthetic strategy of the LPA probe
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Figure 13. Modular synthetic strategy of the LPC probe 
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Experimental Procedure 
 
 
(S)-4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane (3) 
Sodium hydride (518 mg, 12.1 mmol) was dissolved in 40 mL of N,N-
dimethylformamide at 0 oC under Nitrogen gas. S-Glycerol acetonide 2 (1 mL,8.1 
mmol) was then dissolved in 40 mL of N,N-dimethylformamide and slowly added 
to the Sodium hydride solution over 10 min. This mixture was then stirred at 0 oC 
for 1 hour, after which 4-methoxybenzyl chloride (1.64 mL, 12.1 mmol) was 
added at room temperature and stirred overnight at room temperature. This was 
quenched by water (50 mL) the next day.  This was followed by extraction with 
dichloromethane and saturated sodium chloride (2×50 mL), the organic layer was 
collected and dried using magnesium sulphate, then filtered and the solvent was 
removed. Column chromatography on silica gel and a gradient solvent system of 
10-50% ethyl acetate/hexanes gave the product  as a clear oil (1.23 g, 61%). 
1H NMR (300 MHz, CDCl3) δ 7.33 – 7.21 (m, 4H), 6.95 – 6.83 (m, 2H), 4.59 – 
4.43 (m, 2H), 4.27 (dd, J = 12.1, 5.9 Hz, 1H), 4.05 (dd, J = 8.2, 6.4 Hz, 1H), 3.81 
(s, 3H), 3.73 (dd, J = 8.2, 6.4 Hz, 1H), 3.48 (ddd, J = 27.0, 9.8, 5.6 Hz, 2H), 1.61 
– 1.51 (m, 4H), 1.39 (d, J = 17.8 Hz, 5H), 0.23 – -0.25 (m, 38H). 
NMR data matched that in the literature.27  
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(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol (4) 
Acetal 3 (1.63 g, 6.5 mmol) was dissolved in methanol/dichloromethane (1:1, 40 
mL) and p-toluenesulphonic acid (570 mg, 3 mmol) was added, then it was 
allowed to stir at room temperature for 24 hours. The reaction mixture was then 
quenched with sodium bicarbonate (505 mg, 6 mmol) followed by extraction with 
water and dichloromethane (2x50mL) , the organic layer was collected and dried 
using MgSO4, then filtered, and the solvent was removed. Column 
chromatography on silica gel and a gradient solvent system of 50% ethyl 
acetate/hexanes to 5% methanol/dichloromethane gave the diol 4  (682 mg, 
50%).  
1H NMR (300 MHz, CDCl3) δ 7.31–7.21 (m, 1H), 6.90 (dd, J = 9.0, 2.3 Hz, 1H), 
4.50 (s, 1H), 3.96–3.84 (m, 1H), 3.82 (d, J = 0.5 Hz, 1H), 3.77–3.72 (m, 1H), 
3.72–3.67 (m, 1H), 3.63 (dd, J = 11.0, 5.0 Hz, 1H), 3.55 (dd, J = 5.8, 5.1 Hz, 1H), 
3.51 (d, J = 6.1 Hz, 1H). 
 
(S)-1-((4-methoxybenzyl)oxy)-3-((4-
methoxyphenyl)diphenylmethoxy)propan-2-ol (5) 
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The p-methoxybenzyl protected diol 4 (305 mg, 1.4 mmol) was dissolved in 
pyridine (20 mL) under Nitrogen, followed by the addition of monomethoxytrityl 
chloride (889.4 mg, 2.88 mmol), 4-dimethylaminopyridine (17.59 mg, 0.14 mmol) 
and some molecular sieves. The reaction mixture  was then stirred overnight at 
room temperature. Next day, it was quenched by methanol (1 mL) and then 1 
drop of water added and stirred, followed by the removal of solvent. Column 
chromatography on silica gel and a gradient solvent system of 20-35% ethyl 
acetate/hexanes gave the product  5 (524.4 mg, 75%). 
1H NMR (300 MHz, CDCl3) δ 7.39 (dt, J = 9.1, 8.0 Hz, 4H), 7.34 – 7.12 (m, 11H), 
6.93 – 6.73 (m, 4H), 4.60 (s, 1H), 4.46 (s, 2H), 3.98 (dt, J = 10.3, 4.2 Hz, 1H), 
3.82 – 3.73 (m, 6H), 3.62 – 3.45 (m, 2H), 3.20 (pd, J = 9.4, 5.8 Hz, 2H), 2.47 (d, J 
= 4.8 Hz, 1H), 1.64 (s, 1H). 
NMR data matched that in literature. 
 
(S)-tert-butyl((1-((4-methoxybenzyl)oxy)-3-((4-
methoxyphenyl)diphenylmethoxy)propan-2-yl)oxy)diphenylsilane (6) 
Alcohol 5 (204 mg, 0.42 mg) was dissolved in pyridine (5 mL) under nitrogen, 
followed by the addition of imidazole (57.3 mg, 0.84 mmol), t-
butyldiphenylchlorosilane (0.218 mL, 0.84 mmol) and molecular sieves. This 
reaction mixture was then stirred at room temperature overnight. Once the 
reaction was complete, the molecular sieves were removed by filtering the 
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mixture over celite. The mixture was then quenched with 10 mL of methanol and 
then a few drops of water added. This was followed by removal of solvent by 
rotary evaporation, and column chromatography on silica gel and a gradient 
solvent system of 3-10% ethyl acetate/hexanes gave product  6 (302 mg, 99%).  
1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 2H), 7.90–7.76 (m, 4H), 7.63 (t, 
J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.88 (s, 1H), 4.83 (d, J = 5.4 Hz, 1H), 
4.60 (s, 1H), 3.81 (s, 3H), 3.14 (d, J = 6.4 Hz, 2H), 2.04–1.93 (m, 1H), 1.84 (s, 
1H), 1.58 (dd, J = 3.7, 3.0 Hz, 1H), 1.56–1.47 (m, 2H), 1.41 (s, 11H). 
NMR data matched that in literature.27 
 
(R)-2-((tert-butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-1-ol (7) 
Compound 6 (296 mg, 0.41 mmol) was dissolved in methanol:dichloromethane 
(15 mL, 2:1), followed by the addition of camphorsulfonic acid (47.55 mg, 0.20 
mmol). The reaction mixture was then stirred at room temperature for 3.5 hours, 
followed by its neutralization by triethylamine and concentration. Column 
chromatography on silica gel and a gradient solvent system of 20–35% ethyl 
acetate/hexanes gave the product  7 (99 mg, 51%). 
1H NMR (300 MHz, CDCl3) δ 7.72–7.59 (m, 4H), 7.50–7.29 (m, 6H), 7.18–7.05 
(m, 2H), 6.89–6.75 (m, 2H), 4.37–4.19 (m, 2H), 3.99–3.84 (m, 1H), 3.79 (s, 3H), 
3.64 (d, J = 4.3 Hz, 2H), 3.57–3.34 (m, 2H), 1.07 (d, J = 2.9 Hz, 9H). 
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(S)-methyl-2-(4-benzoylbenzamido)-6-((tert-
butoxycarbonyl)amino)hexanoate (9) 
Cbz protected lysine 8 (600 mg, 1.52 mmols) was dissolved in methanol (15 mL), 
followed by the addition of 10% palladium hydroxide (60 mg) by weight. The 
mixture was then stirred for 24 hours at room temperature under hydrogen, 
followed by filtration over celite. Then the filtrate was concentrated, and the 
residue (386.1 mg, 97%) was dissolved in N,N-dimethylformamide (10 mL) under 
nitrogen, followed by the addition of 4-benzoylbenzoic acid (186 mg, 0.82 mmol), 
EDCI (189 mg, 0.99 mmol) and 4-dimethylaminopyridine (120 mg, 0.99 mmol). 
The reaction mixture was stirred at room temperature for 5 hours, and then 
concentrated. Column chromatography on silica gel and a gradient solvent 
system of 50% ethyl acetate/hexanes gave the product  9 (240 mg, 60%). 
1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 2H), 7.90–7.76 (m, 4H), 7.63 (t, 
J = 7.4 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.88 (s, 1H), 4.83 (d, J = 5.4 Hz, 1H), 
4.60 (s, 1H), 3.81 (s, 3H), 3.14 (d, J = 6.4 Hz, 2H), 2.04–1.93 (m, 1H), 1.84 (s, 
1H), 1.58 (dd, J = 3.7, 3.0 Hz, 1H), 1.56–1.47 (m, 2H), 1.41 (s, 11H). 
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(S)-methyl 6-azido-2-(4-benzoylbenzamido)hexanoate (12a) 
Boc-protected amine 9 (30.4 mg, 0.06 mmols) was dissolved in dichloromethane 
(4 mL), followed by the addition of trifluoroacetic acid (4 mL), and the reaction 
mixture was stirred at room temperature for 2 hours. Then it was concentrated, 
and the residue put under high vacuum overnight. The next day, the residue was 
dissolved in methanol (10 mL), followed by the addition of imidazole-1-sulfonyl 
azide hydrochloride (16.35 mg, 0.08 mmols), 0.804 M potassium carbonate 
solution (0.14 mL, 0.11 mmol) and 0.01 M copper (II) sulfate pentahydrate 
solution (0.65 mg, 0.006 mmols). The reaction mixture was stirred at room 
temperature for 3 hours, followed by extraction with ethyl acetate and 2M HCl. 
The organic phase was collected and dried with MgSO4 followed by 
concentration. Column chromatography on silica gel and a gradient solvent 
system of 50% ethyl acetate/hexanes gave the product  12a (21 mg, 80%). 
1H NMR (300 MHz, CDCl3) δ 7.91 (dd, J = 14.1, 6.6 Hz, 3H), 7.88–7.75 (m, 4H), 
7.68–7.57 (m, 1H), 7.57–7.43 (m, 2H), 6.88 (d, J = 7.7 Hz, 1H), 4.87 (dd, J = 
12.9, 7.4 Hz, 1H), 3.82 (s, 3H), 3.37–3.19 (m, 2H), 2.1 –1.95 (m, 1H), 1.86 (ddd, 
J = 20.8, 11.7, 6.4 Hz, 1H), 1.74–1.58 (m, 2H), 1.58–1.38 (m, 2H). 
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NMR data matched that in literature.28 
 
(S)-6-azido-2-(4-benzoylbenzamido)hexanoic acid (13a) 
Azide 12b (355 mg, 0.9 mmol) was dissolved in methanol (4 mL), followed by the 
addition of 2M NaOH (4 mL) was added, and then the reaction mixture stirred at 
room temperature  for 30 minutes. Then the reaction was extracted with 2M HCl, 
and the organic layer collected and dried with magnesium sulfate and 
concentrated to give the product 13a (308 mg, 90%). 
1H NMR (300 MHz, CDCl3) δ 7.89 (dd, J = 19.8, 8.5 Hz, 3H), 7.79 (dd, J = 5.3, 
3.2 Hz, 1H), 7.68–7.57 (m, 1H), 7.50 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 
4.88 (dd, J = 12.9, 7.1 Hz, 1H), 3.32 (t, J = 6.5 Hz, 1H), 2.07 (s, 1H), 1.92 (d, J = 
7.4 Hz, 1H), 1.67 (dt, J = 12.2, 6.0 Hz, 2H), 1.55 (d, J = 4.1 Hz, 2H), 1.25 (s, 4H), 
0.87 (d, J = 7.0 Hz, 1H). 
NMR data matched that in literature.28 
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Acid 13a (57 mg, 0.15 mmol) was dissolved in dichloromethane (5 mL) under 
nitrogen, followed by the addition of a few molecular sieves, 4-
dimethylaminopyridine (25.5 mg, 0.20 mmol) and N,N-dicyclohexylcarbodiimide 
(43 mg,0.20 mmols). This reaction mixture was stirred at room temperature for 
30 minutes. Next, the alcohol 7 (70 mg, 0.15 mmols) was added and the reaction 
mixture was stirred for 24 hours. Then it was filtered over celite and 
concentrated. Column chromatography on silica gel and a gradient solvent 
system of 20-35% ethyl acetate/hexanes gave the product 21 (17 mg, 14%). 
1H NMR (300 MHz, CDCl3) δ 7.99 – 7.89 (m, 1H), 7.90 – 7.76 (m, 4H), 7.75 (s, 
1H), 7.67 (d, J = 8.2 Hz, 5H), 7.53 (t, J = 7.6 Hz, 3H), 7.39 (d, J = 7.4 Hz, 9H), 
7.11 (t, J = 11.3 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 4.70 (s, 1H), 4.48 – 4.40 (m, 
1H), 4.39 – 4.22 (m, 3H), 4.08 (s, 1H), 3.80 (d, J = 9.8 Hz, 20H), 3.66 – 3.57 (m, 
1H), 3.57 – 3.43 (m, 2H), 3.39 (s, 4H), 3.26 (s, 2H), 3.18 – 3.04 (m, 1H), 2.21 (s, 
1H), 2.07 (s, 1H), 1.97 – 1.82 (m, 1H), 1.75 (s, 1H), 1.61 (s, 3H), 1.44 (s, 2H), 
1.27 (s, 5H), 1.12 – 0.96 (m, 9H), 0.88 (d, J = 7.6 Hz, 2H), 0.18 – -0.19 (m, 64H). 
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Acid 13b (30 mg, 0.06 mmol) was dissolved in dichloromethane (5 mL) under 
nitrogen, followed by the addition of a few molecular sieves, 4-
dimethylaminopyridine (10.4 mg, 0.08 mmol) and N,N-dicyclohexylcarbodiimide 
(23 mg, 0.12 mmols). This reaction mixture was stirred at room temperature for 
30 minutes. Next, the alcohol 7 (14 mg, 0.07 mmols) was added and the reaction 
mixture was stirred for 24 hours. Then it was filtered over celite and 
concentrated. Column chromatography on silica gel and a gradient solvent 
system of 75% ethyl acetate/hexanes-10%methanol/dichloromethane gave the 
product 21 (5 mg, 12%). 
1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 7.9 Hz, 2H), 7.93 – 7.72 (m, 4H), 7.63 
(t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.35 – 7.17 (m, 5H), 6.97 – 6.81 (m, 
2H), 6.30 (s, 1H), 6.26 – 6.13 (m, 1H), 4.75 (s, 1H), 4.49 (s, 2H), 4.43 – 4.16 (m, 
1H), 4.11 (s, 1H), 3.97 (dt, J = 5.3, 2.6 Hz, 2H), 3.84 – 3.74 (m, 3H), 3.67 (s, 1H), 
3.54 (dd, J = 8.0, 5.0 Hz, 2H), 3.26 (s, 2H), 2.44 (d, J = 4.8 Hz, 4H), 2.19 (t, J = 
2.5 Hz, 1H), 2.00 (d, J = 26.1 Hz, 3H), 1.65 (s, 6H), 1.57 – 1.32 (m, 6H), 1.32 – 
1.11 (m, 6H), 0.87 (d, J = 7.0 Hz, 2H). 
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4-oxo-4-(prop-2-yn-1-ylamino)butanoic acid (11) 
Propargylamine (1.5 ml, 21.87 mmols) was dissolved in 10 ml of N,N-
dimethylformamide/acetonitrile (1:1) at 0oC under Nitrogen. Next, succinic 
anhydride dissolved in 10 ml of acetonitrile was added to this solution, and stirred 
overnight at room temperature. This was followed by removal of the solvent, and 
the residue was then washed with 40 ml of hexane to obtain a yellow brown 
solid. Column chromatography on silica gel and a gradient solvent system of 20-
50% ethyl acetate/hexanes/0.1% acetic acid-10% methanol/dichloromethane/ 
0.1% acetic acid gave the product 11 (2502 mg, 38%). 
1H NMR (300 MHz, CDCl3) δ 3.93 (t, J = 2.3 Hz, 2H), 3.30 (dt, J = 3.3, 1.6 Hz, 
8H), 2.64 – 2.52 (m, 3H), 2.52 – 2.41 (m, 2H). 
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